Science

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial

Pimavanserin reduced symptoms of dementia-related psychosis in phase 3 trial

New data presented at the Alzheimer’s Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants’ dementia.

Read More…….
EurekAlert!, the online, global news service operated by AAAS, the science society,